Sixarp

Sixarp is a biotechnology company specializing in the development of next-generation radiopharmaceuticals using a pre-targeted radioimmunotherapy (PRIT) platform. Spun out from Memorial Sloan Kettering Cancer Center, the company's technology utilizes the Self-Assembling Disassembling Antibody (SADA) platform to decouple tumor targeting from radioactive payload delivery. This approach is designed to maximize the therapeutic index by allowing the targeting protein to clear from the blood before the radionuclide is administered, thereby reducing off-target toxicity to organs like the bone marrow. Sixarp's lead programs, which are being advanced in collaboration with partners like Y-mAbs Therapeutics, target GD2 for neuroblastoma and GPA33 for colorectal cancer. The company's innovative strategy aims to transform the treatment landscape for both pediatric and adult solid tumors.